2016, Food and Drug Administration and Pharmacology

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2016

Food and Drug Administration

Pharmacology

Patents: a necessary evil?

European Pharmaceutical Review

OCTOBER 19, 2022

1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 4 The initial patents are usually filed during drug discovery. The patent will typically expire after 20 years.

Food and Drug Administration

Food and Drug Administration Pharmaceutical products FDA Pharmacology

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

SEPTEMBER 22, 2023

Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.

Food and Drug Administration

Food and Drug Administration Safety Patients Leads

Pharma Rep Focus

Patents: a necessary evil?

Paving the way for anti-Abeta active immunotherapy

Stay Connected